Brokerages Set Simulations Plus, Inc. (NASDAQ:SLP) Price Target at $17.25

Simulations Plus, Inc. (NASDAQ:SLP) has been assigned an average rating of “Reduce” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $17.25.

Several brokerages have weighed in on SLP. Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target on the stock. in a research note on Thursday, June 18th. Finally, Weiss Ratings upgraded Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the transaction, the director owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Simulations Plus

Hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in Simulations Plus during the second quarter valued at approximately $25,000. Quarry LP purchased a new stake in Simulations Plus during the third quarter worth $28,000. GAMMA Investing LLC lifted its holdings in Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock worth $52,000 after buying an additional 585 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Simulations Plus by 343.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after buying an additional 3,084 shares during the period. Finally, Longfellow Investment Management Co. LLC bought a new stake in Simulations Plus during the 2nd quarter valued at $77,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Simulations Plus stock opened at $18.32 on Thursday. The company has a 50 day moving average price of $17.86 and a 200-day moving average price of $15.38. Simulations Plus has a fifty-two week low of $11.09 and a fifty-two week high of $21.01. The company has a market capitalization of $370.61 million, a PE ratio of 45.80 and a beta of 1.32.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.07. The firm had revenue of $21.89 million during the quarter, compared to analyst estimates of $20.90 million. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%. On average, analysts forecast that Simulations Plus will post 0.8 earnings per share for the current year.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.